SEREVENT DISKUS (50MCG/DOSE) POWDER

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SALMETEROL (SALMETEROL XINAFOATE)

可用日期:

GLAXOSMITHKLINE INC

ATC代码:

R03AC12

INN（国际名称）:

SALMETEROL

剂量:

50MCG

药物剂型:

POWDER

组成:

SALMETEROL (SALMETEROL XINAFOATE) 50MCG

给药途径:

INHALATION

每包单位数:

60 DOSE

处方类型:

Prescription

治疗领域:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

產品總結:

Active ingredient group (AIG) number: 0126960002; AHFS:

授权状态:

APPROVED

授权日期:

2001-07-04

产品特点

_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SEREVENT DISKUS
salmeterol xinafoate dry powder for inhalation
50 mcg salmeterol (as the xinafoate salt)/blister
Bronchodilator
(beta2-adrenergic stimulant)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Initial Approval:
October 25, 1994
Date of Revision:
March 2, 2021
Submission Control No: 243734
_2021 GSK group of companies or its licensor_
_ _
_Trademarks are owned by or licensed to the GSK group of companies _
_ _
_Page 2 of 49_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE
NOT LISTED.
PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 4
1
INDICATIONS ...............................................................................................................
4
1.1
Pediatrics
...............................................................................................................
5
1.2
Geriatrics
...............................................................................................................
5
2
CONTRAINDICATIONS ..............................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................ 6
4
DOSAGE AND ADMINISTRATION ...........................................................................
7
4.1 Dosing Considerations
...............................................................................................
7
4.2 Recommended Dose and Dosage Adjustment
............................................................ 8
4.4 Administration
...........................................................................................................
9
4.5 Missed Dose
..............................................................................................................
9
5
OVERDOSAGE ....................................................................................